Imaging end points for monitoring neuroprotection in Parkinson's disease

Annals of Neurology

Volumn 53, Issue SUPPL. 3, 2003, Pages

  Brooks, David J ^a   Schapira, ^b   Tatton, ^b   Beal, ^b   Stocchi, ^b   Marek, ^b   Olanow, ^b   Rascol, ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; BIOLOGICAL MARKER; CARBON 11; DIHYDROTETRABENAZINE; FLUORINE 18; IODINE 123; LEVODOPA; NEUROPROTECTIVE AGENT; ROPINIROLE;

CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; CLINICAL TRIALS; DOPAMINE; ENDPOINT DETERMINATION; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PUTAMEN; RADIOPHARMACEUTICALS; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0037378772     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10480     Document Type: Review

References (67)

1. Jellinger K. The pathology of parkinsonism. In: Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworths, 1987:124-165.
2. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
3. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworths, 1987:166-230.
4. Byrne E, Lennox G, Lowe J, Godwin-Austin RB. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatr 1989;52:709-717.
5. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38: 1285-1291.
6. Louis DE, Tang MX, Cote L, et al. Progression of parkinsonian signs in Parkinson's disease. Arch Neurol 1999;56:334-337.
7. Fahn S, Elton RL, and members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, eds. Recent developments in Parkinson's disease. New York: Macmillan, 1987:153-163.
8. Martinez-Martin P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson's Disease Rating Scale: characteristics and structure. Mov Disord 1994;9:76-83.
9. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
10. Lang AE, Benabid AL, Koller WC, et al. The Core Assessment Program for Intracerebral Transplantation. Mov Disord 1995; 10:527-528.
11. 18F]dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591.
12. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
13. Ward CD. Does selegiline delay the progression of Parkinson's disease? A critical reevaluation of the DATATOP study. J Neurol Neurosurg Psychiat 1994;57:217-220.
14. Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Disease and Associated Disorders. 1997;11(suppl 5):S10-S20.
15. Firnau G, Sood S, Chirakal R, et al. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 1987;48:1077-1082.
16. 18F]fluorodopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab 1993;13:43-56.
17. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34: 324-330.
18. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993;34:331-338.
19. Yee RE, Huang SC, Stout DB, et al. Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in vivo and in vitro investigations. J Neurochem 2000;74:1147-1157.
20. Yee RE, Irwin I, Milonas C, et al. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord 2001;16:838-848.
21. Diffley DM, Costa JL, Sokoloski EA, et al. Direct observation of 6-fluorodopamine in guinea pig nerve microsacs by 19F NMR Biochem Biophys Res Commun 1983;110:740-745.
22. 18F]fluorodopamine in vivo. J Neurosci Methods 1997; 76:157-165.
23. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiat 1995;59:597-600.
24. 18F-dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J Neurol Sci 1996;136:169-173.
25. 18F] fluorodopa studies. In: Myers R, Cunningham V, Bailey D, Jones T, eds. Quantification of brain function using PET. San Diego: Academic Press, 1996:82-87.
26. Ceravolo R, Piccini P, Bailey DL, et al. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002;43:201-207.
27. 11C-raclopride PET studies. Neurology 1999;52: 932-937.
28. Vingerhoets FJG, Snow BJ, Langston JW, et al. Positron emission tomographic evidence for progression of human MPTPinduced dopaminergic lesions. Ann Neurol 1994;36:765-770.
29. 18F]dopa PET. J Neurol Neurosurg Psychiat 1998;64:314-319.
30. 18F]dopa PET study. Neurology 1999;52(suppl 2):A91.
31. Sawle GV, Colebatch JG, Shah A, et al. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol 1990;28:799-804.
32. Eidelberg D, Takikawa S, Dhawan V, et al. Striatal F-18 dopa uptake - absence of an aging effect. J Cereb Blood Flow Metabol 1993;13:881-888.
33. Laruelle M, Giddings SS, Zea-Ponce Y, et al. Methyl 3 beta(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions. J Neurochem 1994;62:978-986.
34. Seibyl JP, Marek KL, Quinlan D, et al. Decreased singlephoton emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
35. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiat 1997;62:133-140.
36. Seibyl JP, Marek K, Sheff K, et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 1997;38: 1453-1459.
37. Marek K, Seibyl JP, Zoghbi SS, et al. [I-123] beta-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemiparkinsons disease. Neurology 1996;46:231-237.
38. Innis RB, Marek KL, Sheff K, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [I-123]beta-CIT. Mov Disord 1999;14:436-442.
39. Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-2094.
40. Marek KL, Innis RB, Seibyl J. Assessment of Parkinson's disease progression with β-CIT and SPECT imaging. Mov Disord 1998;13(suppl 2):238-230.
41. 123I]-FP-CIT Study Group. Mov Disord 2000;15:503-510.
42. Benamer HTS, Patterson J, Wyper DJ, et al. Correlation of Parkinson's disease severity and duration with I-123-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692-698.
43. Naudon L, Leroux-Nicollet I, Costentin J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra. Neurosci Lett 1994;173:1-4.
44. Frey KA, Koeppe RA, Kilbourn MR, et al. Pre-synaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-884.
45. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
46. Alexander T, Sortwell CE, Sladek CD, et al. Comparison of neurotoxicity following repeated administration of L-dopa, D-dopa, and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fischer 344 and Sprague-Dawley donors. Cell Transplant 1997;6:309-315.
47. Iida M, Miyazaki I, Tanaka K, et al. Dopamine D2 receptormediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999;838:51-59.
48. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998;44(suppl 1):S167-S174
49. Whone AL, Remy P, Davis MR, et al. The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. Neurology 2002;57(suppl 3).
50. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
51. Doder M, Rabiner EI, Turjanski N, et al. Functional imaging of tremor in Parkinson's disease with [C-11]-WAY 100635 PET. Neurology 2001;56(suppl 3):A271-A272.
52. Mulholland GK, Wieland DM, Kilbourn MR, et al. [F-18]Fluoroethoxy-benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses. Synapse 1998;30:263-274.
53. Shiba K, Mori H, Ikeda E, et al. The potential of radioiodinated (-)-m-iodovesamicol for diagnosing cholinergic deficit dementia. Nucl Med Biol 2001;28:261-264.
54. Brown RG, Marsden CD. Cognitive function in Parkinson's disease: from description to theory. TINS 1990;13:21-29.
55. Byrne EJ, Lowe J, Godwin-Austen RB, et al. Dementia of Parkinson's disease associated with diffuse cortical Lewy bodies. Lancet 1987;i:501.
56. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106:257-270.
57. Brown RG, Marsden CD. Visuospatial function in Parkinson's disease. Brain 1986;109:987-1002.
58. Sagar HJ, Sullivan EV, Gabrieli JDE, et al. Temporal ordering and short-term memory deficits in Parkinson's disease. Brain 1988;111:525-539.
59. Foster NL, Chase TN, Mansi L, et al. Cortical abnormalities in Alzheimer's disease. Ann Neurol 1984;16:649-654.
60. Kuhl DE, Metter EJ, Riege WH. Patterns of local cerebral glucose utilisation determined in Parkinson's disease by the 18Ffluorodeoxyglucose method. Ann Neurol 1984;15:419-424.
61. Peppard RF, Martin WRW, Carr GD, et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992;49:1262-1268.
62. Vander-Borght T, Minoshima S, Giordani B, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's disease matched for dementia severity. J Nucl Med 1997;38:797-802.
63. Minoshima S, Foster NL, Sima AA, et al. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50: 358-365.
64. 18 FDG PET study. Brain 2000;123:340-352.
65. Banati RB, Myers R, Kreutzberg GW. PK ("peripheral benzodiazepine")-binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol 1997;26:77-82.
66. Gerhard A, Banati RB, Cagnin A, Brooks DJ. In vivo imaging of activated microglia with [C-11]PK11195 positron emission tomography (PET) in idiopathic and atypical Parkinson's disease. Neurology 2001;56(suppl 3):A270.
67. Remy P, Doder M, Lees AJ, Turjanski N, Hammers A, Brooks DJ. Depression in Parkinson's disease is associated with impaired catecholamine terminal function in the midbrain, thalamus, and anterior cingulate cortex. Neurology 2002;58(suppl 3):A488.